Implications of ejection fraction value for trastuzumab

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7570.704-a (Published 28 September 2006) Cite this as: BMJ 2006;333:704
  1. D Schlosshan, specialist registrar in cardiology (dschlo1038@aol.com),
  2. C Dickinson, consultant cardiologist,
  3. R Sapsford, consultant cardiologist,
  4. D Dodwell, consultant clinical oncologist,
  5. T Perren, consultant clinical oncologist
  1. Leeds General Infirmary, Leeds LS1 3EX
  2. Leeds General Infirmary, Leeds LS1 3EX
  3. St James's University Hospital, Leeds LS9 7TF

    EDITOR—We are concerned about the final appraisal determination document from the National Institute for Health and Clinical Evidence (NICE) for trastuzumab (Herceptin), which gives an absolute left ventricular ejection fraction of 55% as an eligibility criterion for adjuvant or neoadjuvant use in early stage breast cancer.12 The reliance on an absolute ejection fraction …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription